PD-1/CD19 Bispecific Antibody Purification for Autoimmune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bispecific antibodies targeting PD-1 and CD19 have not been effective in preventing or treating autoimmune diseases, and there is a need for a pharmaceutical agent that can effectively interact with PD-1 and PD-L1 to manage autoimmune disease progression or recurrence.
Innovation Solution
A PD-1/CD19 bispecific antibody with specific amino acid sequences in its variable heavy chain regions, allowing easy separation from by-products during purification, and featuring interactions with PD-1 and CD19, is developed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a bisspecific antibody targeting PD-1 and CD19 is developed, then therapeutic effectiveness for autoimmune diseases is improved, but manufacturing complexity and purification difficulty increase
Solution Approach 1:
The bispecific antibody is divided into two functional arms: the first arm binds to PD-1 to enhance immunosuppressive signals, while the second arm binds to CD19 to target B cells. This segmentation allows each arm to perform its specific function independently, improving therapeutic effectiveness while maintaining manageable manufacturing complexity through modular design
Solution Approach 2:
The patent introduces specific amino acid sequences in the heavy chain variable regions as intermediary elements that facilitate binding to PD-1 and CD19. These intermediary sequences act as mediators between the antibody structure and its target molecules, enabling effective interaction without requiring complex overall structure
2Ease of manufacture
If amino acid substitutions are made in the heavy chain variable regions, then ease of separation from by-products is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies local quality changes by introducing specific amino acid substitutions only in the heavy chain variable regions (first and second arms) while maintaining the overall antibody structure. This localized modification improves separability from by-products during purification without requiring high precision throughout the entire manufacturing process
Solution Approach 2:
The patent changes the amino acid sequence parameters in the heavy chain variable regions to create distinctive characteristics that facilitate separation. By modifying specific parameters (amino acid sequences) rather than the overall structure, the patent achieves easier separation while maintaining reasonable manufacturing precision requirements
Data Source
AI summary
An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, containing a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.